IBEX Technologies Past Earnings Performance
Past criteria checks 5/6
IBEX Technologies has been growing earnings at an average annual rate of 58%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 14.1% per year. IBEX Technologies's return on equity is 27.9%, and it has net margins of 49.7%.
Key information
58.0%
Earnings growth rate
57.1%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 14.1% |
| Return on equity | 27.9% |
| Net Margin | 49.7% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
The Market Lifts IBEX Technologies Inc. (CVE:IBT) Shares 27% But It Can Do More
Feb 13
IBEX Technologies' (CVE:IBT) Earnings Might Not Be As Promising As They Seem
Dec 22Market Might Still Lack Some Conviction On IBEX Technologies Inc. (CVE:IBT) Even After 28% Share Price Boost
Dec 19Calculating The Fair Value Of IBEX Technologies Inc. (CVE:IBT)
Oct 05A Look At The Fair Value Of IBEX Technologies Inc. (CVE:IBT)
May 22Shareholders May Be More Conservative With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation For Now
Jan 19We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation
Feb 10Investors Shouldn't Be Too Comfortable With IBEX Technologies' (CVE:IBT) Robust Earnings
Mar 25IBEX Technologies Inc.'s (CVE:IBT) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Feb 22How Should Investors React To IBEX Technologies' (CVE:IBT) CEO Pay?
Dec 29Revenue & Expenses Breakdown
How IBEX Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 8 | 4 | 4 | 1 |
| 31 Oct 23 | 8 | 4 | 3 | 1 |
| 31 Jul 23 | 7 | 4 | 3 | 1 |
| 30 Apr 23 | 8 | 2 | 3 | 1 |
| 31 Jan 23 | 8 | 1 | 3 | 1 |
| 31 Oct 22 | 8 | 2 | 3 | 0 |
| 31 Jul 22 | 8 | 2 | 3 | 0 |
| 30 Apr 22 | 7 | 2 | 3 | 0 |
| 31 Jan 22 | 6 | 1 | 2 | 0 |
| 31 Oct 21 | 6 | 1 | 2 | 0 |
| 31 Jul 21 | 5 | 1 | 2 | 0 |
| 30 Apr 21 | 5 | 1 | 2 | 0 |
| 31 Jan 21 | 6 | 1 | 2 | 0 |
| 31 Oct 20 | 5 | 1 | 2 | 0 |
| 31 Jul 20 | 5 | 1 | 2 | 0 |
| 30 Apr 20 | 5 | 0 | 2 | 0 |
| 31 Jan 20 | 4 | -1 | 2 | 0 |
| 31 Oct 19 | 4 | -1 | 2 | 0 |
| 31 Jul 19 | 4 | -1 | 2 | 0 |
| 30 Apr 19 | 4 | -1 | 2 | 0 |
| 31 Jan 19 | 5 | 0 | 2 | 0 |
| 31 Oct 18 | 5 | 0 | 2 | 0 |
| 31 Jul 18 | 5 | 0 | 2 | 0 |
| 30 Apr 18 | 5 | 2 | 2 | 0 |
| 31 Jan 18 | 5 | 2 | 2 | 0 |
| 31 Oct 17 | 5 | 3 | 2 | 0 |
| 31 Jul 17 | 5 | 3 | 2 | 0 |
| 30 Apr 17 | 5 | 1 | 2 | 0 |
| 31 Jan 17 | 4 | 0 | 2 | 0 |
| 31 Oct 16 | 4 | 0 | 2 | 0 |
| 31 Jul 16 | 4 | 0 | 2 | 0 |
| 30 Apr 16 | 5 | 1 | 2 | 0 |
| 31 Jan 16 | 5 | 1 | 2 | 0 |
| 31 Oct 15 | 4 | 1 | 2 | 0 |
| 31 Jul 15 | 3 | 0 | 2 | 0 |
| 30 Apr 15 | 3 | -1 | 2 | 0 |
| 31 Jan 15 | 3 | -1 | 2 | 0 |
| 31 Oct 14 | 4 | 0 | 2 | 0 |
| 31 Jul 14 | 4 | 0 | 2 | 0 |
| 30 Apr 14 | 4 | 0 | 2 | 0 |
| 31 Jan 14 | 4 | 0 | 2 | 0 |
| 31 Oct 13 | 4 | 0 | 2 | 0 |
| 31 Jul 13 | 4 | 0 | 2 | 0 |
| 30 Apr 13 | 4 | -1 | 2 | 0 |
Quality Earnings: IBT has a high level of non-cash earnings.
Growing Profit Margin: IBT's current net profit margins (49.7%) are higher than last year (17.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IBT's earnings have grown significantly by 58% per year over the past 5 years.
Accelerating Growth: IBT's earnings growth over the past year (187.4%) exceeds its 5-year average (58% per year).
Earnings vs Industry: IBT earnings growth over the past year (187.4%) exceeded the Biotechs industry -8.9%.
Return on Equity
High ROE: IBT's Return on Equity (27.9%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/08 03:50 |
| End of Day Share Price | 2024/04/08 00:00 |
| Earnings | 2024/01/31 |
| Annual Earnings | 2023/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IBEX Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|